Jonathan Brotchie

Dr Jonathan Brotchie is a co-Founder, Director and President of Atuka Inc (2011-present). Dr Brotchie has more than 25 years' experience in Parkinson's disease research, managing teams in both academia and in commercial environments that have identified and validated several drug targets for PD. He has lead translational research that has supported the assessment of efficacy of more than 25 drug candidates in non-human primate models of PD and the advancement of 8 drug candidates to clinical studies. Dr Brotchie has also been named inventor/ co-inventor on 13 families of patents related to novel therapeutics for movement disorders. In addition to Atuka Inc, he has founded, and held senior management positions in, two other successful PD-focussed CROs, Atuka Ltd (Founder and Director, 2003-present) and Motac (CEO and Director, 1999-2002). He has held academic positions at University Health Network, Toronto (2002-present) and University of Manchester (1991-2002). He gained his PhD from University of Manchester, UK for research on the role of the subthalamic nucleus in the generation of symptoms of Parkinson's disease. Dr Brotchie has published more than 100 peer-reviewed academic papers, has sat on the Editorial Board of the journals Movement Disorders and Synapse, he has also consulted for more than 30 biopharmaceutical companies as well as for members for the financial community. He works closely with several Parkinson's charities, as advisor or reviewer of proposals for funding, including Michael J Fox Foundation, Cure Parkinson's Trust and Parkinson Society Canada.